Asahiro Morishita

112PUBLICATIONS
165CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyMedical biochemistry - amino acids and metabolites
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (112)

|Aug 14, 2026
Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 09, 2026
Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic Impact.

|Apr 30, 2026
Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort.

Pageof 19

Frequent Collaborators

46 joint publications

Hidenori Toyoda

41 joint publications

Kazuhito Kawata

40 joint publications

Joji Tani

36 joint publications

Toshifumi Tada